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Abstract 
Laser flash photolysis (LFP) has been used to determine the degree of binding of (S)- or 
(R)-flurbiprofen methyl ester (FBPMe) to human and bovine serum albumins. Regression 
analysis of the triplet decay of the drug (λ = 360 nm) in the presence of the proteins led to a 
satisfactory fitting when considering a set of three lifetimes; the corresponding A1, A2 and A3 
preexponential coefficients can be correlated with the presence of FBPMe in the bulk solution 
and within the two known binding sites. The most remarkable differences between HSA and 
BSA were found under non-saturating conditions; thus, when the [FBPMe]/[SA] ratio was 1:1, 
all the drug was bound to HSA, whereas 20-30 % of it remained free in the bulk solution in the 
presence of BSA. The LFP approach was also applicable to the study of more complex 
FBPMe/HSA/BSA mixtures; the obtained results were in good agreement with the previous 
findings in FBPMe/HSA and FBPMe/BSA systems. This suggests the possibility of making use 
of the transient triplet-triplet absorption for investigating the distribution of a drug between 
several compartments in different host biomolecules. 
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Introduction 
 Serum albumins (SA) are transport proteins very abundant in blood and plasma; one of 
their main functions is to carry several endogenous and exogenous agents (i.e. fatty acids, drugs 
or metabolites) in the bloodstream, to accomplish a selective delivery to specific targets.1,2 
Binding of drugs to SA in biological systems is a key process that can  modulate a number of 
properties of the carried agent, such as increased solubility in plasma, decreased toxicity, 
protection against oxidation or prolongation of the in vivo half-life; hence, binding is essential 
for understanding biodistribution, metabolism, elimination or pharmacological effect of drugs in 
the body. 
 Human (HSA) and bovine (BSA) serum albumins have been widely used as model 
proteins for diverse studies.3-5 Both of them have a well known primary structure and a similar 
folding.6 
The primary structure of HSA, which is synthesized and secreted by the liver, consists of a 
single chain of 585 amino acid residues, with 17 disulfide bridges, one tryptophan (Trp) and one 
free cysteine; the secondary structure is defined by 67% of α helix of six turns, and the three-
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dimensional structure can be described in terms of three domains, each of them constituted in 
turn by two subdomains.7  
Similarly, BSA is also among the most studied proteins in biochemical research; BSA and 
HSA have 76% sequence identity, but BSA contains two Trp residues, instead of one.1  
Binding of small molecules (i.e. drugs or fatty acids) to HSA and BSA has been studied for 
years through different techniques in order to understand the role of transport proteins and also 
to establish the structural basis for designing new therapeutic agents. 8-18 
 Recent studies have found evidence supporting the existence of a high number of binding 
sites in HSA.19,20 However, agreement exists that there are basically two major and structurally 
selective binding sites for small heterocyclic or aromatic compounds, named site I and site II 
according to Sudlow’s classification.21-23 
Likewise, numerous studies on the drug-protein binding process have used BSA as model, 
due to its similarity to HSA.3-5 However, the binding of a variety of ligands to the bovine protein 
has demonstrated to be different from that found for the human protein. 24-36 Several techniques 
have been used for binding studies, including equilibrium dialysis, ultrafiltration, 
ultracentrifugation, calorimetry, fluorescence quenching, circular dichroism, liquid 
chromatography, capillary electrophoresis, NMR diffusion measurements and recently also room 
temperature phosphorescence.8-18 Thus, the development of new tools for the investigation of 
drug-protein interactions, as well as for the comparison between binding of drugs to HSA and 
BSA, seems important to help integration of the existing knowledge. 
Arylpropionic acid derivatives are a group of non-steroidal anti-inflammatory drugs 
(NSAIDs). Currently, they are marketed as racemic mixtures (with few exceptions such as 
naproxen); however, the pharmacological activity is mainly due to the (S)-isomer.37 These drugs 
bind preferentially (and often stereoselectively) to site II of HSA by means of hydrogen bonding 
and electrostatic interactions.38 
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 As the properties of the excited states are very sensitive to the experienced 
microenvironment,39 they could allow to study drug distribution among the bulk solution and the 
different protein binding sites. Previously, time resolved techniques have been employed for the 
study of carprofen-HSA complexes.40,41 However, in this case fast reaction of the drug triplet 
state with the Trp unit of site I limits its possibilities to be used as a probe. This problem can be 
circumvented by choosing “inert” excited states as HSA binding site reporters. Thus, the 
behavior of (S)- and (R)- flurbiprofen (FBP) in the presence of HSA or BSA has been recently 
published.42 Moreover, a significant stereodifferentiation has been observed in the triplet 
lifetimes of the methyl esters of (S)- and (R- FBP (FBPMe) in the presence of HSA (reported as 
a preliminary communication).43 Methylation of the carboxy group is not a trivial structural 
change, as the resulting ester FBPMe binds preferentially to site I, where hydrophobic 
interactions predominate.44 In the present work, we wish to report in full the interaction between 
the excited states of FBPMe (Chart 1) and the binding sites of HSA. These studies have now 
been extended to BSA, as the binding behavior can be significantly different. Remarkably, the 
laser flash photolysis (LFP) technique has proven to be useful to determine the distribution of 
FBPMe between BSA and HSA in mixtures of both proteins, indicating a higher preference for 
the human albumin. This suggests the possibility of making use of the transient triplet-triplet 
absorption for investigating the distribution of a drug between several compartments in different 















Materials and solvents 
The two proteins HSA and BSA were purchased from Sigma; (S)- and (R)-FBP were 
obtained from Aldrich.  
(S)-FBPMe was synthesized by treatment of (S)- or (R)- FBP (200 mg, 0.82 mmol) with 
SOCl2 (0.82 mmol) and MeOH as solvent. The reaction mixture was maintained under reflux 
during 2 h. The organic solvent was removed in vacuo. The remaining oil was dissolved in 
methylene chloride (20 mL), washed with saturated NaHCO3 (twice, 10 mL), 1M HCl  (twice, 
10 mL) and brine (twice, 10 mL). The resulting oil was submitted to silica gel preparative 
chromatography (methylene chloride as eluent) to afford the desired products in nearly 
quantitative yield. 
Solutions of FBPMe/SA in 0.01 M PBS buffer (pH = 7.4) were prepared from Sigma 
phosphate buffered saline tablets. 
 
Absorption spectra 
Optical spectra in different solvents were measured on a Perkin Elmer Lambda 35 UV/Vis 
Spectrophotometer.  
 
Laser flash photolysis experiments 
Laser flash photolysis experiments were performed by using a Q-switched Nd:YAG laser 
(Quantel Brilliant, 266 nm or 355 nm for photosensitized experiments, 4 mJ per pulse, 5 ns 
fwhm) coupled to a mLFP-111 Luzchem miniaturized equipment. All transient spectra were 
recorded employing 10 x 10 mm2 quartz cells with 4 mL of solution. The absorbance of FBPMe 
was ca. 0.2 at the laser wavelength. All the experiments were carried out in phosphate buffer 
(PBS, pH = 7.4, 0.01 M) at room temperature (22 ºC) and under air atmosphere.  
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 For the studies in the presence of SA, a battery of aqueous solutions containing (S)- or 
(R)-FBPMe and SA (molar ratios between 10:1 and 0.5:1) were prepared in neutral buffer (0.01 
M PBS) and stored overnight at 4 ºC to ensure a complete equilibrium between the drug and the 
protein. As an example, the experimental procedure to prepare a solution containing FBPMe and 
SA in 10:1 molar ratio is briefly described: to 20 mL of a 2.5×10-5 M solution of (S)- or (R)-
FBPMe in PBS, 25 µL of SA 2×10-3 M in PBS were added. The resulting solution (4 mL) was 
placed in a quartz cuvette and submitted to LFP (10 shots for monitoring decay at 360 nm). To 
obtain an accurate decay trace, this experiment was repeated at least three times with fresh 
sample; triplet lifetimes and fittings of the decay traces were coincident within the experimental 
error margins. To obtain the transient absorption spectra from 700 to 290 nm, fresh sample (drug 
and protein concentration 2.5×10-5 M) was submitted to LFP in a regular interval of 10 nm (10 
shots per wavelength). 
 
Results and Discussion 
Laser flash photolysis of (S)- and (R)- FBPMe in the presence of HSA 
The first series of studies were focused on the behavior of (S)-FBPMe in HSA. In the 
absence of this protein, the transient absorption spectra obtained after excitation at 266 nm (PBS, 
air) displayed the typical maximum at 360 nm due to the T1→Tn absorption. The decay at 360 
nm followed a first order exponential law with τT = 1.5 µs. For the experiments in the presence 
of HSA, a battery of aqueous solutions containing (S)-FBMe and HSA (molar ratios between 5:1 
and 0.5:1) were prepared in phosphate buffer and submitted to LFP. Remarkably, the decay at 
360 nm in the presence of the protein occurred at longer timescales (Figure 1) and required 
application of a multiexponential function to achieve a satisfactory fitting. 
When the [(S)-FBPMe]/[HSA] ratio was between 1:1 and 0.5:1, a double exponential 
decay was observed with lifetimes of 4.1 and 31.5 µs. The insignificant contribution of the 1.5 
µs component indicated that no free (S)-FBPMe was present in the bulk solution under these 
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conditions. The fact that two different τT values were necessary to fit the decay in the presence 
of HSA would agree with the presence of two different types of microenvironments (i.e., two 
different binding sites) in the protein. The longer triplet lifetimes values of protein-bound (S)-
FBPMe can be due to a slower deactivation of the excited states inside the HSA binding sites; in 
such pockets, a particular microenvironment is created, which is able to protect the triplet 






Figure 1. A. Laser flash photolysis (λexc= 266 nm) of (S)-FBPMe (black), (S)-
FBPMe/HSA 5:1 (red), (S)-FBPMe/HSA 2.5:1 (blue) and (S)-FBPMe/HSA 1:1 (green) in 0.01 
M PBS. B. Laser flash photolysis (λexc= 266 nm) of (R)-FBPMe (black), (R)-FBPMe/HSA 5:1 
(red), (R)-FBPMe/HSA 2.5:1 (blue) and (R)-FBPMe/HSA 1:1 (green) in 0.01 M PBS. The 
normalized decays are monitored at 360 nm. The concentration of (S)- or (R)-FBPMe was 
2.5×10-5 M in all cases.  
At [(S)-FBPMe]/[HSA] ratios from 1.25:1 to 5:1, three lifetime values (1.5, 4.1 and 31.5 
µs) were necessary to obtain a good fitting of the decay signal (some of these decays are also 
shown in Figure 1A). This can be explained taking into account the two (S)-FBPMe/HSA-bound 
species, in addition to free (S)-FBPMe. 
Regression analysis of the decay curves for different [(S)-FBPMe]/[HSA] ratios provided 
the values of the A1, A2 and A3 coefficients associated with the three components of different 
lifetimes, correlated with free, site I-bound and site II-bound FBPMe. Based on the known fact 






















































that the high affinity site of 2-arylpropionic acids methyl esters is site I,43 the major component 
under non-saturating conditions (which was that with the longest τT) was assigned to (S)-FBPMe 
within site I; consequently, the minor component (with τT = 4.1 µs) was assigned to site II-bound 
FBPMe. The distribution of (S)-FBPMe among the binding sites and the bulk solution (provided 
by the A1, A2 and A3 coefficients) is represented in Figure 2 (left). 
In order to look for a possible sterodifferentiation in the binding behavior of the two 
FBPMe enantiomers, a similar study was performed on (R)-FBPMe in the presence of HSA.  
In PBS solution the transient absorption spectra and the triplet lifetimes of the two FBPMe 
enantiomers did not differ from each other, as expected. By contrast, when the [(R)-
FBPMe]/[HSA] ratio was between 1:1 and 0.5:1, a double exponential decay was observed with 
lifetimes values of τT 157.6 µs and 16.6 µs were found for (R)-FBPMe (Figure 1B). These values 
were much higher than those obtained for (S)-FBPMe, indicating a remarkable 
stereodifferentiation between the two enantiomers in the protein binding process. 
At [(R)-FBPMe]/[HSA] ratios from 1.25:1 to 5:1, three lifetime values were again 
necessary to obtain a good fitting of the decay signal; they corresponded to the two (R)-
FBMe/HSA-bound species (τT = 16.6 and 157.5 µs), in addition to free (R)-FBPMe (τT = 1.5 µs). 
As in the case of (S)-FBPMe, the major component under non-saturating conditions (the 
one with τT = 157.6 µs) was assigned to (R)-FBPMe within site I and the minor component (with 
τT = 16.6 µs) to site II-bound FBPMe. From the A1, A2 and A3 coefficients, the distribution of 















Figure 2.  Percentage of FBPMe: free (white), in site I (green) and in site II (orange) of HSA 
from the A1, A2 and A3 values of the multiexponential decay at 360 nm. Left. (S)-FBPMe. 
Right. (R)-FBPMe. 
As a control experiment, in order to ensure that the observed stereodifferentiation in the 
decay kinetics was real, the behavior of racemic FBPMe in the presence of HSA was compared 
with that of the pure enantiomers. In agreement with the expectations, the decay obtained at 360 
nm for a 1:1 FBPMe/HSA molar ratio was perfectly matched by the semi sum of the decays of 





Figure 3. Decay of the 360 nm band obtained by laser flash photolysis (λexc= 266 nm) of 
racemic FBPMe/HSA 1:1 (black), (S)-FBPMe/HSA 1:1 (blue) and (R)-FBPMe/HSA 1:1 
(magenta). The ester concentration was 2.5 × 10-5 M in all cases. The red line corresponds to the 

















































































Laser flash photolysis of (S)- and (R)- FBPMe in the presence of BSA 
To investigate the behavior of (S)-FBPMe within the bovine protein, parallel experiments 
were carried out in the presence of different amounts of BSA. Thus, PBS solutions of (S)-
FBPMe and BSA (molar ratio in the range from 5:1 to 0.5:1) were submitted to LFP. Again, two 
components with τT = 4.6 and 19.3 µs were obtained for the triplet decay (λ = 360 nm) inside the 
protein. This is shown in Figure 4A. 
Regression analysis of the decay curves for [(S)-FBPMe]/[BSA] ratios from 5:1 to 0.5:1 
(where some free drug is present) allowed us to obtain the values of the A1, A2 and A3 
coefficients. The major component under non-saturating conditions (τT = 19.3 µs) was assigned 
to (S)-FBPMe in the high affinity binding site (site I), while the minor component (with τT = 4.6 
µs) was attributed to (S)-FBPMe within site II. These results indicate that, again, the triplet 
excited state of (S)-FBPMe is more protected against deactivation (due to attack by a second (S)-
FBPMe molecule, oxygen, other reagents, etc.) within the microenvironment provided by site I 
in BSA. 
The triplet excited state of site I-bound (S)-FBPMe lived longer within BSA than within 
HSA (ca. 1.5 times); however, no significant differences were found in the corresponding values 
of site II-bound (S)-FBPMe (4.6 vs. 4.1 µs).  
Concerning the site occupancy, as estimated from the A coefficients of the regression 
analysis curves, Figure 5 (left) shows that the main differences between the behavior of the two 
proteins were found at low [(S)-FBPMe]/[SA] ratios. Thus, when the ratio was 1:1, all the 
FBPMe was bound to the human protein, whereas more than 30 % of it remained free in the bulk 
solution in the presence of the bovine protein, under otherwise identical experimental conditions 
(compare Figs. 2 and 5). 
Similar studies were carried out for (R)-FBPMe in the presence of BSA. As usually, from 
the LFP kinetic decays of (R)-FBPMe/BSA solutions (Figure 4), two values of τT (2.8 and 19.7 











Figure 4. A. Laser flash photolysis (λexc= 266 nm) of (S)-FBPMe (black), (S)-
FBPMe/BSA 5:1 (red), (S)-FBPMe/BSA 2.5:1 (blue) and (S)-FBPMe/BSA 1:1 (green) in 0.01 M 
PBS. B. Laser flash photolysis (λexc= 266 nm) of (R)-FBPMe (black), (R)-FBPMe/BSA 5:1 
(red), (R)-FBPMe/BSA 2.5:1 (blue) and (R)-FBPMe/HSA 1:1 (green) in 0.01 M PBS. The 
normalized decays are monitored at 360 nm. The concentration of (S)- or (R)-FBPMe was 2.5·10-
5 M in all cases. 
The site occupancy is shown in Figure 5 (right), confirming the trend observed for the (S)-
enantiomer. The main differences between the behavior of the two proteins were found again at 















































































Figure 5.  Percentage of FBPMe: free (white), in site I (green) and in site II (orange) of 
BSA from the A1, A2 and A3 values of the multiexponential decay at 360 nm. Left. (S)-FBPMe. 
Right. (R)-FBPMe. 
  
 Competition studies on human versus bovine protein occupancy 
As stated above, the most remarkable differences between HSA and BSA as carrier 
proteins for FBPMe were found under non-saturating conditions. A similar behavior was 
observed for the two FBPMe enantiomers.  
This fact suggested the possibility of making use of the transient triplet-triplet absorption 
for investigating the distribution of a drug between several compartments in different host 
biomolecules. To proof the concept, an experiment was designed in which (R)-FBPMe was 
added to a mixture of HSA and BSA in buffered aqueous solution (molar ratio 1.4:1:1). Of 
course, this is not a real situation, but it could be a good model to check the feasibility of this 
new methodology.  
When the (R)-FBPMe/HSA/BSA mixture was flash-photolyzed at 266 nm, the expected 
transient absorption spectrum was obtained corresponding to the typical biphenyl-like T-T band 
with λmax = 360 nm. For the regression analysis of the decay at the absorption maxima, four 
lifetime components (identical to the τT values in sites I and II of both albumins) were assumed. 









































following values: site I of HSA, 55%; site II of HSA, 26%; site I of BSA, 12 %; and site II of 
BSA, 7 %.  These results support that the affinity for the human protein is higher under the non-








Figure 6. Laser flash photolysis (λexc= 266 nm) of (R)-FBPMe/HSA/BSA at molar ratio 
1.4:1.0:1.0. The red trace corresponds to the simulated decay, assuming that the triplet lifetimes 
are the same as in the experiments without mixing the proteins, and using the following 
percentages of occupancy: site I of HSA, 55%; site II of HSA, 26%; site I of BSA, 12 %; and 
site II of BSA, 7 %. 
Conclusions 
Using flurbiprofen methyl ester as a probe, it has been demonstrated that the laser flash 
photolysis technique constitutes a valuable tool for the study of drug binding to transport 
proteins. Regression analysis of the decay kinetics of the transient absorption spectra 
corresponding to the triplet-triplet absorption provides precise information on the number of 
binding sites and their degree of occupancy. Triplet lifetimes inside the binding sites are in 
general much longer than in the bulk aqueous solution and depend on the nature of the sites, on 
the origin (human or bovine) of the employed serum albumin, and/or on the stereochemistry of 
the drug. Although similar trends are observed in HSA and BSA, the main differences between 



























the two proteins are found under non-saturating conditions; thus, when the [FBPMe]/[SA] ratio 
is 1:1, all the drug is bound to HSA, whereas 20-30 % of it remains free in the bulk solution in 
the presence of BSA. Finally, the results obtained using mixtures of the two proteins suggest the 
possibility of making use of the transient triplet-triplet absorption for investigating the 
distribution of a drug between several compartments in different host biomolecules. 
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The figures show the percentage of free (white), site I-bound (green) and site II-bound 
(orange) (S)-FBPMe as obtained from the A1, A2 and A3 values of the multiexponential decay of 
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